JJP-BIOLOGICS
JJP Biologics, a company that specializes in the development of proprietary biologic agents for personalized medicine approaches, has announced that the European Commission has approved the company’s application for designation of its product candidate JJP-1212 as an orphan medicinal product for treatment of Linear IgA Bullous Dermatosis (LABD). Following the European Medicines Agency’s recommendation, the European Commission has confirmed that the intention to treat this condition with JJP-1212 justified orphan drug status based on in vitro and in vivo non-clinical data showing the reduction in the influx of granulocytes into the basement membrane zone of the skin and reduction of inflammatory biomarkers, addressing the key elements of LABD skin blistering pathogenesis.
LABD is a chronically debilitating disease and may lead to blindness and blister formation. Moreover, currently no approved treatments are available for LABD in the European Union. The European Commission has confirmed that, as of the day of submitting the application, LABD could affect approximately 0.3 in 10,000 persons in the European Union.1
“The orphan drug designation of JJP-1212 by the EMA validates the scientific and business choices of JJP Biologics. It was confirmed that JJP-1212 targets the central mechanism in LABD by antagonizing the IgA-CD89 interaction” according to Louis Boon, the Chief Scientific Officer at JJP Biologics. “We are very excited to offer a potential novel therapy for patients suffering from this ultra-rare skin disease with currently unmet needs”.
Having this drug classified into the group of orphan medicinal products provides scientific advice and protocol assistance of the agency. “This decision by the European Commission has also a substantial streamlining effect on the clinical development timeline. We feel the responsibility to translate this decision into prompt availability of the therapy for patients” states Paweł Szczepański, the Chief Operations Officer at JJP Biologics.
About JJP Biologics:
JJP Biologics sp. z o.o. is a biotechnology company that specializes in the development of proprietary biologic agents accompanied by companion diagnostics to allow therapy personalization. JJP Biologics is a privately funded biotech which pursues the development of its own product candidates as well as projects executed in cooperation with scientific partners. The company’s programs target general immune pathways that have application in autoimmune diseases and cancer. JJP Biologics currently has a range of programs including the most advanced JJP-1212 program and an anti-CD270 program for immune oncology. https://jjpbiologics.com/
1 JJP Biologics performed a systematic review of the published literature and the relevant EU databases (list items)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221018006075/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting udvider sine kapaciteter i Asien og Stillehavsområdet med VDB Loi12.9.2025 17:43:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kapaciteter i Cambodja, Vietnam og Laos, da VDB Loi føjer rådgivningsydelser til sit eksisterende udbud af tjenester inden for skat og jura. VDB Loi, som ledes af administrerende direktør Jean Loi, der også fungerer som administrerende direktør for Andersen i Cambodja og Vietnam, blev grundlagt i 2012 som et skatte- og advokatfirma og har siden 2021 samarbejdet med Andersen Global. Med tilføjelsen af dets samlet udvalg af konsulentydelser er VDB Loi nu medlem af Andersen Consulting og tilbyder helhedsorienterede løsninger inden for forretningsstrategi, kunstig intelligens, teknologisk transformation og cybersikkerhed, hvilket komplementerer firmaets eksisterende platform til forhold inden for skat og jura. "Vi har været en del af Andersen-familien i flere år nu og anerkender den værdi og synergi, denne tværfaglige tilgang giver vores klienter," udtalte Jean. "I det nuværende erhvervsklima er det ikke tilstrækkeligt kun at være et skattefirma eller et ju
Allied Nations Gather to Discuss Future of Multilateral Defence Security Financing12.9.2025 17:35:00 CEST | Press release
The Defence, Security and Resilience Bank (DSRB) Development Group co-hosted an international conference in the City of London this week to discuss the creation of a new multilateral bank designed to bring capital market expertise to the frontlines of global security. The event at Mansion House, co-hosted by the Lord Mayor of London, included 72 attendees from 37 countries across the NATO alliance, the EU, and Indo-Pacific allied nations. Held on the eve of the Defence and Security Equipment International (DSEI event), the DSRB “Information Day” event also included a further 88 attendees from a wide range of institutions including the European Union, NATO, eight partner commercial banks, multiple development and central banks as well as representatives from global funds, ratings agencies, industry associations and think tanks. Notes to Editors: The DSR Bank Development Group is a non-profit working toward the establishment of the full bank alongside nation states and institutions. The
Illumination and Nintendo Announce the New Animated Film Based on the World of Super Mario Bros. Will Be Titled The Super Mario Galaxy Movie12.9.2025 15:33:00 CEST | Press release
Illumination (HQ: Santa Monica, CA, USA; Founder and CEO: Chris Meledandri) and Nintendo Co., Ltd. (HQ: Kyoto, Minami-ku, Japan; Representative Director and President: Shuntaro Furukawa, “Nintendo” hereafter) today announced that the title of the new animated film based on the world of Super Mario Bros., will be The Super Mario Galaxy Movie. The film will be released worldwide by Universal Pictures beginning April 3, 2026. In addition, the two companies announced that the returning voice actors for the characters will be: Mario (Chris Pratt), Princess Peach (Anya Taylor-Joy), Luigi (Charlie Day), Bowser (Jack Black), Toad (Keegan-Michael Key), and Kamek (Kevin Michael Richardson). The additional characters and voice cast for The Super Mario Galaxy Movie will be announced at a later date. The Super Mario Galaxy Movie will be released on April 3, 2026 in the US and many additional markets globally, and will be released on April 24, 2026 in Japan, with select territories releasing through
TON Strategy Company Announces Initial Share Repurchases Under $250 Million Program, Buying Below Treasury Asset Value Per Share, and Start of Staking12.9.2025 14:30:00 CEST | Press release
Repurchased over 250,000 shares of common stock under previously announced share repurchase program, at prices below Treasury Asset Value (TAV) per share, which stood at $12.18 as of September 11, 2025 Has begun staking of $TON holdings, as planned, creating a recurring source of on-chain revenues in addition to long-term treasury appreciation TON Strategy Company (Nasdaq: TONX) (the “Company”), a digital asset treasury company committed to holding Toncoin ($TON), today announced that it has repurchased over 250,000 shares of its common stock under its previously announced $250 million share repurchase program. Further, the Company has started staking operations, as planned, to generate on-chain income by utilizing its treasury holdings. The Company repurchased shares at an average of $8.32 per share; by comparison, the Company’s TAV per share was $12.181 as of September 11, 2025. This week’s share repurchases and the start of staking underscore TON Strategy Company’s financial strengt
Ant Group’s AI Healthcare App AQ Users Reach 140 Million, 60% from Tier-three and Lower-Tier Cities12.9.2025 13:38:00 CEST | Press release
At the 2025 INCLUSION · Conference on the Bund in Shanghai, Ant Group’s AI-powered healthcare app AQ has rolled out a new suite of service updates aimed at making healthcare more inclusive and accessible. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250912715926/en/ Ant Group’s AI healthcare app supports users’ daily health needs, extending doctors’ reach beyond time and space. “We hope AI can empower doctors by extending their reach to more patients, freeing up time for medical research and the fight against complex diseases, while equipping community doctors with powerful AI assistants,” said Cyril Han, CEO of Ant Group. Since AQ’s official launch in China in June 2025, following public testing that began in September 2024, the app has served 140 million users, with 60% coming from third-tier cities and below. It offers more than 100 AI-powered services to support users in their daily healthcare needs, including doctor r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom